Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Two phase I open‐label studies were conducted to investigate the pharmacokinetics (PK), safety, and tolerability of single oral doses of selumetinib in subjects with end‐stage renal disease (ESRD) undergoing hemodialysis and subjects with varying degrees of hepatic impairment; both studies included...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Main Authors: Dymond, Angela W., Martin, Paul, So, Karen, Huang, Yifan, Severin, Paul, Holmes, Victoria, Mariani, Gabriella, Marbury, Thomas
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2016
Assuntos:
Special Populations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412920/
https://ncbi.nlm.nih.gov/pubmed/28019010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.848
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares